Mendus AB (IMMUN)

Currency in SEK
3.820
-0.175(-4.38%)
Real-time Data·

IMMUN Earnings

Latest Release
Nov 11, 2026
EPS / Forecast
-0.35 / -0.48
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/12--/-0.460--/0.000----Free Sign Up
2026/09-0.350/-0.4800.000/0.000+27.08%--Free Sign Up
2026/06-0.340/--0.000/------Free Sign Up
2026/03-0.340/--0.000/------Free Sign Up
2025/12-0.740/-0.831--/--+10.91%--Free Sign Up
2025/09-0.370/-0.659--/--+43.83%--Free Sign Up
2025/06-0.450/-0.538--/--+16.28%--Free Sign Up
2025/03-0.610/-0.7291.34M/--+16.3%--Free Sign Up
2024/12-0.630/-0.685-4.29M/0.000+7.98%--Free Sign Up
2024/09-0.702/-0.4600.000/0.000-52.61%--Free Sign Up

All numbers in SEK

Mendus AB Earnings Call Summary for Q3/2026

  • Mendus posted Q3 2026 operating loss of SEK 21M with zero revenue; cash position at SEK 55.7M, runway extended to Q2 2027 via SEK 46.5M Fenja loan.
  • Year-to-date cash burn improved 12.2% to SEK 56.4M from SEK 64.3M; stock declined 3.92% to $4.78, near lower end of 52-week range.
  • Company completed safety stage of VITAL-CML trial, its first chronic myeloid leukemia study, targeting patients on long-term tyrosine kinase inhibitors.
  • Multiple 2027 catalysts expected: VITAL-CML top-line data mid-year, CADENCE first readout H1, DIVA safety data H1 and efficacy H2.
  • CEO Manting emphasized pursuit of 'functional cure' in CML; company expanding manufacturing with NorthX and planning pediatric AML program with MD Anderson.
Last Updated: 2026-11-11, 08:36 a/m
Read Full Transcript

FAQ

What Is Mendus AB's Earnings Per Share (TTM)?

The Mendus AB EPS (TTM) is -1.73.

When Is The Next Mendus AB Earnings Date?

Mendus AB will release its next earnings report on Feb 11, 2027.

What Is Mendus AB’s Revenue Forecasts For Upcoming Quarters?

Mendus AB’s revenue forecast is 0.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.